Michael Crow

Michael Crow supports the Centers for Disease Control and Prevention’s Office of Acquisition Services as a key procurement professional responsible for facilitating mission-critical acquisitions in public health science and emergency response. He manages complex contract actions spanning laboratory diagnostics, biomedical research, and epidemiological data systems, ensuring alignment with CDC’s mandate to detect, prevent, and respond to infectious disease threats. His work directly enables the agency’s scientific infrastructure by securing advanced analytical tools, clinical testing platforms, and high-throughput sequencing capabilities essential for national health surveillance. Crow maintains consistent contracting relationships with leading providers in life sciences and public health infrastructure, including General Dynamics Information Technology, Cepheid, MRIGLOBAL, GlaxoSmithKline, and the New York City Health & Hospitals Corporation. These partnerships reflect a focus on high-reliability vendors capable of delivering validated diagnostic assays, laboratory automation systems, and large-scale public health data solutions under stringent regulatory and quality control standards. His procurement approach emphasizes technical rigor, performance-based outcomes, and long-term operational sustainability over transactional vendor relationships. Crow’s contracting portfolio exhibits no set-aside preferences, with 100% of awards issued under full and open competition. This reflects a strategic emphasis on technical capability and mission readiness over socioeconomic classifications, prioritizing the most qualified providers regardless of business size or certification status. While small business participation is not formally incentivized, vendors are evaluated strictly on technical merit, past performance, and ability to meet CDC’s demanding scientific and operational requirements. His primary procurement focus lies in NAICS 541715 for research and development in life sciences and NAICS 922160 for fire protection services—indicating dual expertise in advanced biomedical R&D and public health emergency infrastructure. He routinely procures next-generation molecular diagnostic systems, biosafety equipment, data analytics platforms, and laboratory capacity-building solutions, demonstrating deep domain knowledge in infectious disease detection and public health preparedness.